Primary prevention of diabetic retinopathy with fibrates: a retrospective, matched cohort study. Issue 12 (3rd December 2013)

• Record Type: Journal Article
• Authors: Morgan, Christopher Ll; Owens, David R; Aubonnet, Patrick; Carr, Emma S M; Jenkins-Jones, Sara; Poole, Chris D; Currie, Craig J
• Is Part Of: BMJ open. Volume 3:Issue 12(2013)
• Publication Date: 2013-12-03
• Subjects: Diabetes & Endocrinology -- Fibrate; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2013-004025
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: To compare the progression of diabetic retinopathy (DR) in people with type 2 diabetes treated with fibrates with that of non-exposed controls. Design: Retrospective, matched cohort study. Setting: UK Clinical Practice Research Datalink (CPRD). Participants: 5038 people with type 2 diabetes with a history of fibrate exposure but without evidence of DR were identified. Three thousand one hundred and seventy-six (63%) people could be randomly matched to one non-exposed control; of these, 2599 (81.8%) were matched without any missing blood pressure or glycated haemoglobin (HbA1c) values. Main outcome measures: The primary endpoint was first recorded DR with a secondary endpoint of all-cause mortality or first DR. Time to clinical endpoints was compared using Cox proportional hazards models. Results: Mean follow-up was 5.1 and 5.0 years for fibrate-exposed and non-exposed patients, respectively. For fibrate-exposed participants, there was a reduction in DR: 33.4 events/1000 person-years vs 40.4 (p=0.002), and in death or DR: 50.6 vs 60.2 (p<0.001). For those matched with full systolic blood pressure and HbA1c data, crude event rates were 34.3 versus 43.9 for DR (p<0.001) and 51.2 vs 63.4 (p<0.001) for death or DR. Following adjustment, DR was significantly delayed for those treated with fibrates, with an adjusted HR (aHR) of 0.785 (p<0.001) for participants with complete data and an aHR of 0.802 (p<0.001) for all participants. Conclusions: The treatment with fibrates in people with type 2 diabetes was independently associated with reduced progression to a first diagnosis of DR.